Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05350501 · ClinicalTrials.gov registry record · Phase 2
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
A Phase 2 study, sponsored by Enterome.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05350501 is a Phase 2 study that was terminated before completion, run by Enterome. The registered enrollment target is 1 participants.
The verdict
NCT05350501, a Phase 2 study, was terminated before completion, sponsored by Enterome.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.
Interventions
- DRUG EO2040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05350501
The ClinicalTrials.gov registry entry for NCT05350501 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enterome, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EO2040 is the first listed.
NCT05350501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05350501 about?
NCT05350501 is a clinical study titled "EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer". The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.
What is the current status of trial NCT05350501?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-03-01. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT05350501?
The interventions under investigation include: EO2040 (DRUG).
Who is sponsoring clinical trial NCT05350501?
This trial is sponsored by Enterome, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.